A Phase I Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) in Healthy Male Subjects
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Capivasertib (Primary) ; Capivasertib (Primary) ; Capivasertib (Primary)
- Indications Male breast cancer; Prostate cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 21 Jul 2022 Status changed from active, no longer recruiting to completed.
- 24 Jun 2022 Planned End Date changed from 15 Jul 2022 to 4 Jul 2022.
- 24 Jun 2022 Planned primary completion date changed from 15 Jul 2022 to 4 Jul 2022.